Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2025-03-04 DOI:10.1158/2643-3230.BCD-24-0153

Christopher R Flowers, Rachel W Anantha, Veronica Leautaud, Pinkal Desai, Chancellor E Donald, Michelle A T Hildebrandt, Jean L Koff, Rulla M Tamimi, Wendy Cozen, Chijioke Nze, Ari M Melnick

引用次数: 0

Abstract

Significance: This review underscores our shared responsibility to champion multidimensional strategies rooted in basic and translational science, community involvement, and societal responsiveness for a meaningful impact. Unifying themes include the need to enhance collaborative infrastructure to engage laboratory researchers, epidemiologists, data scientists, clinicians, patients, community leaders, and policymakers; patient-level support services; outreach, education, and navigation for patients at the community level; recruitment and retention of underrepresented groups in the healthcare and research workforce; and funding for these efforts.

查看原文本刊更多论文

解决血液恶性肿瘤的健康差异：从基因到外展。

意义：本综述强调了我们共同的责任，即支持植根于基础科学和转化科学、社区参与和社会响应的多维战略，以产生有意义的影响。统一的主题包括需要加强协作基础设施，以吸引实验室研究人员、流行病学家、数据科学家、临床医生、患者、社区领袖和政策制定者；患者支持服务；在社区层面为患者提供外展、教育和指导；在医疗保健和研究人员队伍中招募和保留代表性不足的群体；以及为这些努力提供资金。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.